Medivir AB's Simeprevir Has Been Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C Infection
Stockholm, Sweden — Medivir AB (OMX: MVIR) today reports that Janssen Pharmaceutical R&D Ireland (Janssen) has been informed by the Japanese Ministry of Health, Labour and Welfare (MHLW) that simeprevir has been approved for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection.
Help employers find you! Check out all the jobs and post your resume.